News | December 24, 2021
Indian Pharmaceutical Market grew at 6.6 pc in November
Flattish volume growth and subdued new launches were key factors for last month
Flattish volume growth and subdued new launches were key factors for last month
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
Acute therapies continue to report strong growth compared to chronic ones.
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
Subscribe To Our Newsletter & Stay Updated
